Extensive Preclinical Validation of Combined RMC-4550 and LY3214996 Supports Clinical Investigation for KRAS Mutant Pancreatic Cancer

The authors report on the combined inhibition of SHP2, upstream of KRAS, using the allosteric inhibitor RMC-4550 and of ERK, downstream of KRAS, using LY3214996.